79 related articles for article (PubMed ID: 29339252)
1. Structure-based design of human immuno- and constitutive proteasomes inhibitors.
Richy N; Sarraf D; Maréchal X; Janmamode N; Le Guével R; Genin E; Reboud-Ravaux M; Vidal J
Eur J Med Chem; 2018 Feb; 145():570-587. PubMed ID: 29339252
[TBL] [Abstract][Full Text] [Related]
2. Exploration of the carmaphycins as payloads in antibody drug conjugate anticancer agents.
Almaliti J; Miller B; Pietraszkiewicz H; Glukhov E; Naman CB; Kline T; Hanson J; Li X; Zhou S; Valeriote FA; Gerwick WH
Eur J Med Chem; 2019 Jan; 161():416-432. PubMed ID: 30384045
[TBL] [Abstract][Full Text] [Related]
3. Immunoproteasome β5i-Selective Dipeptidomimetic Inhibitors.
Singh PK; Fan H; Jiang X; Shi L; Nathan CF; Lin G
ChemMedChem; 2016 Oct; 11(19):2127-2131. PubMed ID: 27561172
[TBL] [Abstract][Full Text] [Related]
4. Exploration of novel four-membered-heterocycle constructed peptidyl proteasome inhibitors with improved metabolic stability for cancer treatment.
Wang H; Wu Z; Cao Y; Gao L; Shao J; Zhao Y; Zhang J; Zhou Y; Wei G; Li J; Zhu H
Bioorg Chem; 2023 Sep; 138():106626. PubMed ID: 37295239
[TBL] [Abstract][Full Text] [Related]
5. Substituted quinolines as noncovalent proteasome inhibitors.
McDaniel TJ; Lansdell TA; Dissanayake AA; Azevedo LM; Claes J; Odom AL; Tepe JJ
Bioorg Med Chem; 2016 Jun; 24(11):2441-2450. PubMed ID: 27112450
[TBL] [Abstract][Full Text] [Related]
6. Fragment-Sized and Bidentate (Immuno)Proteasome Inhibitors Derived from Cysteine and Threonine Targeting Warheads.
Kollár L; Gobec M; Proj M; Smrdel L; Knez D; Imre T; Gömöry Á; Petri L; Ábrányi-Balogh P; Csányi D; Ferenczy GG; Gobec S; Sosič I; Keserű GM
Cells; 2021 Dec; 10(12):. PubMed ID: 34943940
[TBL] [Abstract][Full Text] [Related]
7. 3D-QSAR-aided design, synthesis, in vitro and in vivo evaluation of dipeptidyl boronic acid proteasome inhibitors and mechanism studies.
Lei M; Feng H; Wang C; Li H; Shi J; Wang J; Liu Z; Chen S; Hu S; Zhu Y
Bioorg Med Chem; 2016 Jun; 24(11):2576-2588. PubMed ID: 27117691
[TBL] [Abstract][Full Text] [Related]
8. Substrate-guided optimization of the syringolins yields potent proteasome inhibitors with activity against leukemia cell lines.
Totaro KA; Barthelme D; Simpson PT; Sauer RT; Sello JK
Bioorg Med Chem; 2015 Sep; 23(18):6218-22. PubMed ID: 26296913
[TBL] [Abstract][Full Text] [Related]
9. Differential Interactions of the Proteasome Inhibitor PI31 with Constitutive and Immuno-20S Proteasomes.
Wang J; Kjellgren A; DeMartino GN
Biochemistry; 2024 Apr; 63(8):1000-1015. PubMed ID: 38577872
[TBL] [Abstract][Full Text] [Related]
10. Enzymatically Formed Peptide Assemblies Sequestrate Proteins and Relocate Inhibitors to Selectively Kill Cancer Cells.
He H; Liu S; Wu D; Xu B
Angew Chem Int Ed Engl; 2020 Sep; 59(38):16445-16450. PubMed ID: 32521103
[TBL] [Abstract][Full Text] [Related]
11. Macrocyclic Peptides that Selectively Inhibit the
Zhang H; Hsu HC; Kahne SC; Hara R; Zhan W; Jiang X; Burns-Huang K; Ouellette T; Imaeda T; Okamoto R; Kawasaki M; Michino M; Wong TT; Toita A; Yukawa T; Moraca F; Vendome J; Saha P; Sato K; Aso K; Ginn J; Meinke PT; Foley M; Nathan CF; Darwin KH; Li H; Lin G
J Med Chem; 2021 May; 64(9):6262-6272. PubMed ID: 33949190
[TBL] [Abstract][Full Text] [Related]
12. Structure-Activity Relationship Studies of Antimalarial
Zhang H; Ginn J; Zhan W; Leung A; Liu YJ; Toita A; Okamoto R; Wong TT; Imaeda T; Hara R; Michino M; Yukawa T; Chelebieva S; Tumwebaze PK; Vendome J; Beuming T; Sato K; Aso K; Rosenthal PJ; Cooper RA; Liverton N; Foley M; Meinke PT; Nathan CF; Kirkman LA; Lin G
J Med Chem; 2023 Jan; 66(2):1484-1508. PubMed ID: 36630286
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and biological evaluation of bone-targeted proteasome inhibitors for multiple myeloma.
Agyin JK; Santhamma B; Roy SS
Bioorg Med Chem Lett; 2013 Dec; 23(23):6455-8. PubMed ID: 24119559
[TBL] [Abstract][Full Text] [Related]
14. Cell-Based Optimization of Covalent Reversible Ketoamide Inhibitors Bridging the Unprimed to the Primed Site of the Proteasome β5 Subunit.
Stubba D; Bensinger D; Steinbacher J; Proskurjakov L; Salcedo Gómez Á; Schmidt U; Roth S; Schmitz K; Schmidt B
ChemMedChem; 2019 Dec; 14(23):2005-2022. PubMed ID: 31675179
[TBL] [Abstract][Full Text] [Related]
15. The 26S proteasome is a multifaceted target for anti-cancer therapies.
Grigoreva TA; Tribulovich VG; Garabadzhiu AV; Melino G; Barlev NA
Oncotarget; 2015 Sep; 6(28):24733-49. PubMed ID: 26295307
[TBL] [Abstract][Full Text] [Related]
16. Discovery of Highly Selective Inhibitors of the Human Constitutive Proteasome β5c Chymotryptic Subunit.
Zhan W; Li D; Saha P; Wang R; Zhang H; Ajay AK; Deban C; Sukenick G; Azzi J; Lin G
J Med Chem; 2023 Jan; 66(2):1172-1185. PubMed ID: 36608337
[TBL] [Abstract][Full Text] [Related]
17. Structure of human immunoproteasome with a reversible and noncompetitive inhibitor that selectively inhibits activated lymphocytes.
Santos RLA; Bai L; Singh PK; Murakami N; Fan H; Zhan W; Zhu Y; Jiang X; Zhang K; Assker JP; Nathan CF; Li H; Azzi J; Lin G
Nat Commun; 2017 Nov; 8(1):1692. PubMed ID: 29167449
[TBL] [Abstract][Full Text] [Related]
18. Modulation of proteasome subunit selectivity of syringolins.
Tatsumi K; Kitahata S; Komatani Y; Katsuyama A; Yakushiji F; Ichikawa S
Bioorg Med Chem; 2024 May; 106():117733. PubMed ID: 38704960
[TBL] [Abstract][Full Text] [Related]
19. Development and characterization of proteasome inhibitors.
Bo Kim K; Fonseca FN; Crews CM
Methods Enzymol; 2005; 399():585-609. PubMed ID: 16338383
[TBL] [Abstract][Full Text] [Related]
20. Bioinspired total synthesis and human proteasome inhibitory activity of (-)-salinosporamide A, (-)-homosalinosporamide A, and derivatives obtained via organonucleophile promoted bis-cyclizations.
Nguyen H; Ma G; Gladysheva T; Fremgen T; Romo D
J Org Chem; 2011 Jan; 76(1):2-12. PubMed ID: 21047113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
